Among patients with ovarian cancer, the objective response rate by RECIST 1.1 criteria was 20% ([14/71], 95% CI: 11–31%), by GCIC (CA-125) criteria 35% ([23/35], 95% CI: 24–48%), and by using RECIST 1.1 and/or CA-125 criteria 30% ([24/80], 95% CI: 20–41%). Here, MUC16 is linked to ovarian carcinoma.